SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Allard P, Fradet Y, Têtu B, Bernard P. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional call carcinoma of the bladder. Clin Cancer Res. 1995; 1: 11951202.
  • 2
    Allard P, Bernard P, Fradet Y, Têtu B. The early clinical course of primary Ta and T1 bladder cancer. A proposed prognostic index. Br J Urol. 1998; 81: 692698.
  • 3
    Kroft SH, Oyasu R. Biology of disease. Urinary bladder cancer: mechanisms of development and progression. Lab Invest. 1994; 71: 158174.
  • 4
    Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer. 1993; 53: 365370.
  • 5
    Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994; 331: 12591264.
  • 6
    Lipponen P. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer. 1993; 29: 749753.
  • 7
    Ye DW, Zheng JF, Qian SX, Ma YJ. Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of the bladder tumors. Urol Res. 1993; 21: 3943.
  • 8
    Korkolopoulou P, Christodoulou P, Kapralos P, et al. The role of p53, MDM2 and c-erbB-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol Res Pract. 1997; 193: 767775.
  • 9
    Bilim V, Tomita Y, Kawasaki T, Katagiri A. Prognostic value of bcl-2 and p53 expression in urinary tract transitional cell cancer. J Natl Cancer Inst. 1996; 88: 686688.
  • 10
    Lipponen PK, Aaltomaa S, Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumours. Histopathology. 1996; 28: 135140.
  • 11
    Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA. The prevalence of bcl-2, p53 and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol. 1998; 29: 146154.
  • 12
    Mulder AH, Van Hootegem JC, Sylvester R, et al. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J Pathol. 1992; 166: 3743.
  • 13
    Asakura T, Takano Y, Iki M, et al. Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol. 1997; 158: 385388.
  • 14
    Popov Z, Hoznek A, Colombel M, et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer. 1997; 80: 14721481.
  • 15
    Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson ML. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erbB-2, epidermal growth factor receptor, and bcl-2. Cancer. 1998; 82: 715723.
  • 16
    Gontero P, Casetta G, Zitella A, et al. Evaluation of p53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol. 2000; 38: 287296.
  • 17
    Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer. 2000; 88: 25982605.
  • 18
    Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, p53, and Ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol. 2000; 163: 758760.
  • 19
    Lipponen PK, Eskelinen MJ. Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value. Br J Cancer. 1992; 66: 171176.
  • 20
    Vorreuther R, Hake R, Borchmann P, Lukowsky S, Thiele J, Engelmann U. Expression of immunohistochemical markers (PCNA, Ki67, 486p and p53) on paraffin sections and their relation to the recurrence rate of superficial bladder tumors. Urol Int. 1997; 59: 8894.
  • 21
    Ioakim-Liossi AG, Karakitsos PJ, Pantazopoulos D, Aroni KG, Athanossiadou P. Image cytometric DNA analysis and proliferating cell nuclear antigen (PCNA) expression in transitional cell carcinoma of the bladder. Cancer Detect Prev. 1999; 23: 401407.
  • 22
    Lipponen PK, Eskelinen MJ, Nordling S. Nucleolar organiser regions (AgNORs) as predictors in transitional cell bladder cancer. Br J Cancer. 1991; 64: 11391144.
  • 23
    Tomobe M, Shimazui T, Uchida K, Hinotsu S, Akaza H. Argyrophilic nucleolar organizer region in proliferating cell has a predictive value for local recurrence in superficial bladder tumor. J Urol. 1999; 162: 6368.
  • 24
    Blomjous EC, Schipper NW, Baak JP, Vos W, De Voogt HJ, Meijer CJ. The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinoma. Am J Clin Pathol. 1989; 91: 243248.
  • 25
    Blomjous EC, Vos W, Schipper NW, et al. The prognostic significance of selective nuclear morphometry in urinary bladder carcinoma. Hum Pathol. 1990; 21: 409413.
  • 26
    van Velthoven R, Petein M, Oosterlinck W, et al. Identification by quantitative chromatin pattern analysis of patients at risk for recurrence of superficial transitional bladder carcinoma. J Urol. 2000; 164: 21342137.
  • 27
    Mostofi FK, Davis CJ, Sesterhenn IA. Histological typing of urinary bladder tumours (2nd edition). Berlin: Springer, 1999: 811.
  • 28
    Sobin LH, Wittekind CH. TNM classification of malignant tumors (5th edition). New York: Wiley-Liss, Inc., 1997: 187190.
  • 29
    Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Navone R. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. Am J Surg Pathol. 2001; 25: 15281533.
  • 30
    Öfner D, Riedmann B, Maier H, et al. Standardized staining and analysis of argyrophilic nucleolar organizer region associated proteins (AgNORs) in radically resected colorectal adenocarcinoma. Correlation with tumour stage and long-term survival. J Pathol. 1995; 175: 441448.
  • 31
    Pfister C, Lacombe L, Vezina MC, et al. Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. Hum Pathol. 1999; 30: 13501355.
  • 32
    O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer. 1991; 63: 444446.
  • 33
    Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J Clin Pathol. 1996; 49: 395399.
  • 34
    Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 35
    Cox DR. Regression models and life tables (with discussion). J R Stat [B]. 1972; 34: 187220.
  • 36
    DixonWJ, BrownMG, EngelmanL, HillMA, JennrichRI, eds. BMPD statistical software manual. Berkeley: University of California Press, 1990.
  • 37
    Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R, Haapasalo H. Grading of superficial bladder cancer by quantitative mitotic frequency analysis. J Urol. 1993; 149: 3641.
  • 38
    Lipponen P. Image analysis of Ag-NOR proteins in transitional cell bladder cancer. J Pathol. 1993; 171: 279283.
  • 39
    Derenzini M, Sirri V, Trerè D, Ochs RL. The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Lab Invest. 1995; 73: 497502.
  • 40
    Dong H, Bertler C, Schneider E, Ritter MA. Assessment of cell proliferation by AgNOR scores and Ki-67 labeling indices and a comparison with potential doubling times. Cytometry. 1997; 28: 280288.
  • 41
    Serth J, Kuczyk MA, Bokemeyer C, et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer. 1995; 71: 201205.
  • 42
    Têtu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P. Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer. J Urol. 1996; 155: 17841788.
  • 43
    Tzai TS, Chow NH, Lin JS, Yang WH, Tong YC. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in outcome of postoperative intravesical chemotherapy. Anticancer Res. 1998; 18: 47174721.
  • 44
    Pfister C, Moore L, Allard P, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res. 1999; 5: 40794084.
  • 45
    Lipponen P, Eskelinen M, Syrjanen S, Tervahauta A, Syrjanen K. Use of immunohistochemically demonstrated c-erbB-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol. 1991; 20: 238242.
  • 46
    Orlando C, Sestini R, Vona G, et al. Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique. J Urol. 1996; 156: 20892093.